

TAYSIDE PRESCRIBER

ADTC Supplement

No. 18

May 2002

In this issue:

- **Report from the Drug Evaluation Panel**
- **Report from the Patient Group Directions Sub-Committee**
- **Tayside Area Drug Formulary 2002**
- **Scottish Medicines Consortium**
- **ADTC Intranet Site Development**

Drug Evaluation Panel – New Drug Evaluations

Fibrin Glue (Quixil®, Omrix Biopharmaceuticals)

Category 2a: Hospital use only

Human Fibrinogen/Thrombin mixture approved for use in repair of fistulae in ano and recurrent anorectal fistulae (unlicensed indication)

Atosiban (Tractocile®, Ferring Pharmaceuticals)

Category 2a: Hospital use only

Tocolytic agent to delay imminent preterm birth in pregnant women. Approved for use in place of the beta-agonists on safety grounds or nifedipine which is unlicensed for this indication.

InnoLet® Insulin Administration Device

Category 1a: Recommendation for general use.

Compliance aid for administration of Mixtard 30 and Insulatard insulins in suitable diabetic patients e.g. impaired vision or poor dexterity.

Sibutramine (Reductil®)

Category 1b: may be included in specialist protocols or have a limited role in treatment pathways. Previous Xenical® guidelines will be revised to include sibutramine. Note that clinical support is no longer available via the Obesity Clinic which was closed in 2001.

Patient Group Directions (PGDs)

The following have been approved for implementation.

- Administration of Salbutamol by Nursing Staff in Cases of Acute Asthma
- Administration of Rectal Diazepam by Nursing Staff in Cases of Epilepsy

Copies of PGDs are available on the ADTC Website, see Intranet/Internet Site below.

Tayside Area Drug Formulary

The 7th Edition of the Formulary will be published later this year. It will contain updated Gastro-intestinal and Cardiovascular guidelines and a further series of guidelines on drug therapy in Dermatology, Respiratory disease and Psychiatric illness.

Scottish Medicines Consortium (SMC)

The SMC is now operational. Details of membership and minutes of meetings are available on their website, see www.scottishmedicines.org.uk. A detailed work programme is pending. Meanwhile press statements have been issued on the following new drugs.

- Pegylated interferon alfa-2b (Viraferon Pega®) in hepatitis C infection
- Imatinib mesylate (Glivec®) in chronic myeloid leukaemia

Intranet/Internet Site

Further development of the ADTC website has taken place and minutes of the meetings of the ADTC are now available, see site location below.

www.tayside.scot.nhs.uk/nhstayside/intranet (go to Committees → NHS Tayside → Drug and Therapeutics Committee).

Comments or further information on items published in **ADTC Supplement** can be obtained from the ADTC Secretary on [www.doreen.wilkie@tuht.scot.nhs.uk](mailto:doreen.wilkie@tuht.scot.nhs.uk)